CapUn Point Laboratories Limited
CORPORATE OFFICE: Ashvich Tower, 3rd Floor,
CAPLIN POINT® No.3, Developed Plots Industrial Estate, Perungudi, Chennai - 600096.
Phone : +91 44 24968000 / +91 80127 72888
Laboratories
E-mail :
[email protected] /Website: www.caplinpoint.net
CIN : L24231TN1990PLC019053
13.05.2019
BSE Limited
Department of Corporate Relationship
ist Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742 By BSE Listing
National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai - 400 051
Scrip Code : CAPLIPOINT. By NEAPS
Dear Sirs,
Sub : PRESS RELEASE - DISCLOSURE UNDER REGULATION 30 OF SEBI {LISTING OBLIGATIONS
OF DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.
We wish to inform exchanges that, the Company has received Colombia's INVIMA approval
for its small volume sterile injectable division at Puducherry.
Please find the enclosed Press Release for the above .
Thanking You,
Yours Truly,
For Caplin Point Laboratories Limited
Q~~
Co~y Secret ary
Enclosure: As Above
Ragd. Off. : "NARBAVI", No. 3, Lakshmanan Street, T.Nagar, Chennai - 600 017. Tamil Nadu, India. Ph.: +914428156653.
Utllt I : No. 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: 95242 32888 / 95242 32006.
Unit II : No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondl Taluk, Thiruvallur District - 601 201. Ph.: 9445391317.
Ulllt Ill : Plot No. 44, 8th Avenue, Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Kanchlpuram District-603 004.
Unit IV : Survey No. 895 & 897, Guruvarajakandigai, Sirupuzhalpettal (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9788459333 / 69333.
Ulllt V : Ashvich Tower, 2nd Floor, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096. Ph.: +91 44 24968000.
PRESS RELEASE
CAPLIN POINT GETS COLOMBIA APPROVAL FOR STERILE INJECTABLES
Chennai, May 13, 2019: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE:
CAPLIPOINT) has received Colombia's INVIMA approval for its small volume sterile
injectable division at Puducherry. The site inspection of Unit-1 was completed on May
10th and found compliant as per INVIMA's norms of Good Manufacturing Practices
(GMP) and Good Laboratory Practices (GLP). The facility is capable of manufacturing
Liquid lnjectables in Vials, Ampoules, Lyophilized Vials and Pre-Filled Syringes,
amongst other dosage forms.
Commenting on the approval, Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories
Limited said "Colombia is part of our expansion plans into the larger markets of Latin
America. It also happens to be our first approval from Unit-1 site at Puducherry. We'll
be focusing on niche opportunities in lnjectables in these newer geographies."
Unit-1 site currently caters to Emerging Markets of Latin America and Africa with a
variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories,
Liquid Orals and Topicals.
ABOUT CAPLIN POINT LABORATORIES LIMITED:
Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a
unique business model catering predominantly to emerging markets of Latin America
and Africa. Caplin Point Laboratories Limited has state of the art manufacturing
facilities that cater to a complete range of finished dosage forms. The Company has
also entered regulated markets such as US through its Wholly Owned Subsidiary
Caplin Steriles Limited,
Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three
consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging
Company of 2018" by Economic Times Family Business Awards.
CAUTIONARY STATEMENT:
This press release contains certain forward-looking statements. Any forward-looking
statement applies only on the date of this press release. By their nature, forward-
looking statements are subject to a number of known and unknown risks and
uncertainties that may or may not occur in the future and as a result of which the
actual results and performance may differ substantially from the expected future
results or performance expressed or implied in the forward-looking statements. No
warranties or representations are made as to the accuracy, achievement or
reasonableness of such statements, estimates or projections, and Caplin Point has no
obligation to update any such information or to correct any inaccuracies herein or
omission here from which may become apparent.
For details, please contact:
Investor Relations Team at Caplin Registered Office
Mr.Vined Kumar (Company Secretary) Narbhavi No. 3, Lakshmanan Street,
Tel: +91 44 24968000 T Nagar, Chennai, Tamil Nadu, 600017
[email protected] Telephone: 044-28156653
CIN: L24231TN1990PLC019053
Dikshita Jain ISIN: INE475E01026
Christensen Investor Relations NSE Code: CAPLIPOINT
Tel : +91 22 4215 0210 BSE CODE: 524742
d
[email protected] Website: www.caplinpoint.net
